Results 41 to 50 of about 4,490 (182)

Characterization of exogenous αSN response genes and their relation to Parkinson’s disease using network analyses

Frontiers in Pharmacology, 2022
Despite extensive research, the molecular mechanisms underlying the toxicity of αSN in Parkinson’s disease (PD) pathology are still poorly understood.
Zahra Nayeri, Zahra Nayeri, Farhang Aliakbari, Farhang Aliakbari, Farzaneh Afzali, Soha Parsafar, Ehsan Gharib, Daniel E. Otzen, Dina Morshedi   +8 more
doaj   +1 more source

Entrectinib Induces Apoptosis and Inhibits the Epithelial–Mesenchymal Transition in Gastric Cancer with NTRK Overexpression

, 2021
Tropomyosin receptor kinase (TRK) and receptor tyrosine kinase (RTK class VII) expression are important in many human diseases, especially cancers, including colorectal, lung, and gastric cancer.
Hyeong Su Kim, Dae Young Zang, Sung-Hwa Sohn, Bum Jun Kim, Hee Jung Sul   +4 more
core   +1 more source

BIOANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF ENTRECTINIB IN RAT PLASMA BY LIQUID CHROMATOGRAPHY–TANDEM MASS SPECTROMETRY [PDF]

, 2020
Objective: The objective of the study was to develop and validate the bioanalytical liquid chromatography–mass spectrometry (LCMS/MS) method for the estimation of entrectinib in bulk and pharmaceutical drugs in rat plasma.
KE, PRAVALLIKA, RANI A, PRAMEELA, KUMAR M, RATNA   +2 more
core   +1 more source

Entrectinib-Induced Pericarditis with Cardiac Tamponade in a Patient with Neurotrophic Tropomyosin Receptor Kinase 1 Fusion-Positive Breast Cancer

Case Reports in Oncology
Introduction: Entrectinib is a multikinase inhibitor used to treat neurotrophic tropomyosin receptor kinase (NTRK) fusion-positive, locally advanced, or metastatic tumors. Cardiovascular events, such as congestive heart failure and myocarditis,
Aki Aoyama, Yutaro Yoshitomi, Akihiko Shimomura, Yukino Kawamura, Tomoko Taniyama, Atsumasa Kurozumi, Shuji Kubota, Yukio Hiroi, Chikako Shimizu   +8 more
doaj   +1 more source

ROS1 in non-small-cell lung carcinoma: A narrative review

Cancer Research, Statistics, and Treatment, 2022
ROS1 rearranged non-small-cell lung cancer (NSCLC) is a distinct molecular subtype of NSCLC, accounting for 2% of cases. Typically, these are genomic rearrangements resulting in a fusion oncoprotein that causes unabated constitutive signaling.
Shrinidhi Nathany, Ullas Batra, Rashi Sachdeva, Mansi Sharma, B P Amrith, Shriya Vaidya   +5 more
doaj   +1 more source

Entrectinib-induced Brugada syndrome leading to ventricular tachycardia in a patient with ROS1 fusion-positive lung adenocarcinoma

European Journal of Case Reports in Internal Medicine
A 65-year-old male presented to the emergency room after experiencing syncope while driving, causing a self-inflicted accident. He had previously been diagnosed with stage IV A (cTXN2M1a) lung adenocarcinoma with C-ROS oncogene 1 (ROS1) fusion gene ...
Nobuo Ishiguro, Takeshi Mori, Makito Kaneshiro, Shin Hasegawa, Akimitsu Tanaka, Miyuki Ando, Kazuo Kato   +6 more
doaj   +1 more source

Entrectinib-related myocarditis in a young female patient with metastatic non-small cell lung cancer [PDF]

, 2021
A 51-year-old woman presented with a 2-week history of off balance, left lower limb weakness and neglect and neck pain radiating down the right arm. Investigations revealed a metastatic, ROS1 fusion-positive, non-small cell lung cancer, and treatment ...
Chen, DH, Ghosh, AK, Fonseca, M, Walker, JM   +3 more
core   +1 more source

A Unified Hierarchical Multiscale Fusion Framework for Drug–Target Affinity Prediction: From Benchmark Performance to Nanomolar Inhibitor Discovery

Advanced Science, EarlyView.
A multimodal fusion framework integrating sequence, atomic, and fragment representations captures drug–target interactions across multiple scales. The model delivers strong predictive performance and enables efficient virtual screening. Applied to hematopoietic progenitor kinase 1 (HPK1), it identifies structurally diverse inhibitors with nanomolar ...
Shuo Liu, Xiang Zhang, Haixia Feng, Yuquan Li, Xiaoqing Gong, Yong Liang, Xiaojun Yao, Huanxiang Liu   +7 more
wiley   +1 more source

TRK Inhibitors: Tissue-Agnostic Anti-Cancer Drugs

Pharmaceuticals, 2021
Recently, two tropomycin receptor kinase (Trk) inhibitors, larotrectinib and entrectinib, have been approved for Trk fusion-positive cancer patients. Clinical trials for larotrectinib and entrectinib were performed with patients selected based on the ...
Sun-Young Han
doaj   +1 more source

Impact of extended insurance coverage on survival outcomes among patients with metastatic colorectal cancer in Taiwan

British Journal of Clinical Pharmacology, EarlyView.
Aims Predetermined treatment duration limits (PTDLs) are often used by Taiwan's National Health Insurance Administration to contain healthcare costs, but they may compromise patient outcomes. Therefore, we studied Taiwan's 2017 extension of the bevacizumab PTDL from 24 to 36 weeks in metastatic colorectal cancer (mCRC) to evaluate whether prolonged ...
Wei‐Ming Huang, Chen‐Han Chueh, Chien‐Yu Tseng, Christopher N. Kaufmann, Earl J. Morris, Chiao‐En Wu, Yi‐Wen Tsai   +6 more
wiley   +1 more source